Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI

Tarin, Carlos; Carril, Mónica; Martin-Ventura, José Luis; Markuerkiaga, Irati; Padró, Daniel; Llamas-Granda, Patricia; Moreno, Juan Antonio; Garcı́a, Isabel; Genicio, Nuria; Plaza-García, Sandra; Blanco-Colio, Luís Miguel; Penadés, Soledad; Egido, Jesús

doi:10.1038/srep17135

Cited by 67 publications

(55 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tarin et al developed an atherosclerotic plaque targeting probe based on gold-coated iron oxide nanoparticles modified with an anti-CD163 antibody. It binds specifically to the membrane receptor CD163 over-expressed by macrophages at inflammatory sites such as atherosclerotic plaques [218]. El-Dakdouki et al decorated magnetic glyconanoparticles with hyaluronan, which selectively binds to CD44 overexpressed by macrophages within vulnerable plaques [219].…”

Section: Nanoparticle-based Theranostics For Dysfunctional Macrophmentioning

confidence: 99%

Nanomedicines for dysfunctional macrophage-associated diseases

Ghosh

Yang

2017

Journal of Controlled Release

View full text Add to dashboard Cite

Macrophages play vital functions in host inflammatory reaction, tissue repair, homeostasis and immunity. Dysfunctional macrophages have significant pathophysiological impacts on diseases such as cancer, inflammatory diseases (rheumatoid arthritis and inflammatory bowel disease), metabolic diseases (atherosclerosis, diabetes and obesity) and major infections like human immunodeficiency virus. In view of this common etiology in these diseases, targeting the recruitment, activation and regulation of dysfunctional macrophages represents a promising therapeutic strategy. With the advancement of nanotechnology, development of nanomedicines to efficiently target dysfunctional macrophages can strengthen the effectiveness of therapeutics and improve clinical outcomes. This review discusses the specific roles of dysfunctional macrophages in various diseases and summarizes the latest advances in nanomedicine-based therapeutics and theranostics for treating diseases associated with dysfunctional macrophages.

show abstract

Section: Nanoparticle-based Theranostics For Dysfunctional Macrophmentioning

confidence: 99%

Nanomedicines for dysfunctional macrophage-associated diseases

Ghosh

Yang

2017

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…The advantages and disadvantages of PET, CTCA, and MRI techniques are summarized in Table 4. [124, [126][127][128]134,139,140] Note: CTCA-computed tomographic coronary angiography; MRI-magnetic resonance imaging; PET-positron emission tomography.…”

Section: Magnetic Resonance Imagingmentioning

confidence: 99%

Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque

Mushenkova¹,

Summerhill

Zhang

et al. 2020

IJMS

View full text Add to dashboard Cite

Atherosclerosis is a lipoprotein-driven inflammatory disorder leading to a plaque formation at specific sites of the arterial tree. After decades of slow progression, atherosclerotic plaque rupture and formation of thrombi are the major factors responsible for the development of acute coronary syndromes (ACSs). In this regard, the detection of high-risk (vulnerable) plaques is an ultimate goal in the management of atherosclerosis and cardiovascular diseases (CVDs). Vulnerable plaques have specific morphological features that make their detection possible, hence allowing for identification of high-risk patients and the tailoring of therapy. Plaque ruptures predominantly occur amongst lesions characterized as thin-cap fibroatheromas (TCFA). Plaques without a rupture, such as plaque erosions, are also thrombi-forming lesions on the most frequent pathological intimal thickening or fibroatheromas. Many attempts to comprehensively identify vulnerable plaque constituents with different invasive and non-invasive imaging technologies have been made. In this review, advantages and limitations of invasive and non-invasive imaging modalities currently available for the identification of plaque components and morphologic features associated with plaque vulnerability, as well as their clinical diagnostic and prognostic value, were discussed. Int. J. Mol. Sci. 2020, 21, 2992 2 of 26 by the low and oscillatory endothelial shear stress [3]. According to the current understanding, lesion development involves lipid accumulation in the arterial intima, resulting in foam cell formation, a local inflammatory response, and migration and proliferation of several cell types, including macrophages, smooth muscle cells (SMCs), lymphocytes, neutrophils, and dendritic cells that play a pivotal role in its progression. Lipid accumulation is a key event in the formation of the atherosclerotic lesion, and it is determined by different classes of lipoproteins [4]. Atherosclerotic plaque tends to develop early in life [5], progressing with age; however, the progression rate is not completely predictable and varies among individuals. In general, it undergoes a prolonged asymptomatic phase (lasting many years or several decades) until the manifestation of the first clinical symptoms often at the later stages of atherosclerosis. The mechanisms of plaque progression encompass SMC apoptosis, matrix synthesis, angiogenesis, arterial remodeling, fibrous cap rupture, and thrombosis, followed by necrosis and calcification. The most acute cardiovascular events are triggered by the rupture; erosion; or, the least common, calcified nodule, the vulnerable plaque phenotypes, followed by coronary thrombosis. Ruptured lesions are responsible for the majority (73%) of all ACSs [6]. In addition, the underlying mechanism of sudden coronary death from thrombi was found from plaque erosions, in 30%-35% of cases, and rarely from calcified nodules, in 2%-7% of cases [7].The biological features of two major classes of high-risk (vulnerable) plaques, such as rupture-pron...

show abstract

“…In that sense, Nahrendorf and colleagues enhanced a dextran-coated, cross-linked and, for additional conjugation, aminated iron oxide nanoparticle with a near-infrared fluorochrome and the radiotracer 64 Cu, derivatized with the chelator DTPA. This combined paramagnetic, positron-emitting and fluorescent targeted iron oxide nanoparticle ( 64 Cu-TNP) was then tested against 18 FDG in an ApoE-deficient mouse model. CT-contrast was achieved by additional infusion of an iodinated contrast agent.…”

Section: Macrophagesmentioning

confidence: 99%

Small Dimension—Big Impact! Nanoparticle-Enhanced Non-Invasive and Intravascular Molecular Imaging of Atherosclerosis In Vivo

et al. 2020

View full text Add to dashboard Cite

Extensive translational research has provided considerable progress regarding the understanding of atherosclerosis pathophysiology over the last decades. In contrast, implementation of molecular in vivo imaging remains highly limited. In that context, nanoparticles represent a useful tool. Their variable shape and composition assure biocompatibility and stability within the environment of intended use, while the possibility of conjugating different ligands as well as contrast dyes enable targeting of moieties of interest on a molecular level and visualization throughout various imaging modalities. These characteristics have been exploited by a number of preclinical research approaches aimed at advancing understanding of vascular atherosclerotic disease, in order to improve identification of high-risk lesions prior to oftentimes fatal thromboembolic events. Furthermore, the combination of these targeted nanoparticles with therapeutic agents offers the potential of site-targeted drug delivery with minimized systemic secondary effects. This review gives an overview of different groups of targeted nanoparticles, designed for in vivo molecular imaging of atherosclerosis as well as an outlook on potential combined diagnostic and therapeutic applications.

show abstract

Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI

Cited by 67 publications

References 31 publications

Nanomedicines for dysfunctional macrophage-associated diseases

Nanomedicines for dysfunctional macrophage-associated diseases

Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque

Small Dimension—Big Impact! Nanoparticle-Enhanced Non-Invasive and Intravascular Molecular Imaging of Atherosclerosis In Vivo

Contact Info

Product

Resources

About